Export 39 results:
Author Title Type [ Year(Asc)]
Filters: Author is Hill, Heather  [Clear All Filters]
2022
G. J. Gorse, Grimes, S., Buck, H., Mulla, H., White, P., Hill, H., May, J., Frey, S. E., and Blackburn, P., “MAS-1, A Novel Water-In-Oil Adjuvant/Delivery System, With Reduced Seasonal Influenza Vaccine Hemagglutinin Dose May Enhance Potency, Durability and Cross-Reactivity of Antibody Responses in the Elderly”, Vaccine, vol. 40, no. 10, pp. 1472-1482, 2022.
G. J. Gorse, Grimes, S., Buck, H., Mulla, H., White, P., Hill, H., May, J., Frey, S. E., and Blackburn, P., “A Phase 1 Dose-Sparing, Randomized Clinical Trial of Seasonal Trivalent Inactivated Influenza Vaccine Combined With MAS-1, A Novel Water-In-Oil Adjuvant/Delivery System”, Vaccine, vol. 40, no. 9, pp. 1271-1281, 2022.
2021
S. E. Frey, Stapleton, J. T., Ballas, Z. K., Rasmussen, W. L., Kaufman, T. M., Blevins, T., Jensen, T. L., D Davies, H., Tary-Lehman, M., Chaplin, P., Hill, H., and Goll, J. B., “Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated and antibody dependent cellular cytotoxicity responses.”, J Infect Dis, 2021.
P. Winokur, Sahly, H. M. El, Mulligan, M. J., Frey, S. E., Rupp, R., Anderson, E. J., Edwards, K. M., Bernstein, D. I., Schmader, K., Jackson, L. A., Chen, W. H., Hill, H., and Bellamy, A., “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
R. Salerno-Gonçalves, Chen, W. H., Mulligan, M. J., Frey, S. E., Stapleton, J. T., Keitel, W. A., Bailey, J., Sendra, E., Hill, H., Johnson, R. A., and Sztein, M. B., “Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
2020
L. Lai, Rouphael, N., Xu, Y., Sherman, A. C., Edupuganti, S., Anderson, E. J., Lankford-Turner, P., Wang, D., Keitel, W., McNeal, M. M., Cross, K., Hill, H., Bellamy, A. R., and Mulligan, M. J., “Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., “Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
2019
S. L. Hillier, Ferrieri, P., Edwards, M. S., Ewell, M., Ferris, D., Fine, P., Carey, V., Meyn, L., Hoagland, D., Kasper, D. L., Paoletti, L. C., Hill, H., and Baker, C. J., “A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.”, Clin Infect Dis, vol. 68, no. 12, pp. 2079-2086, 2019.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
2017
L. M. Howard, Hoek, K. L., Goll, J. B., Samir, P., Galassie, A., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Prasad, N., Jensen, T. L., Hill, H., Levy, S. E., Joyce, S., Link, A. J., and Edwards, K. M., “Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.”, PLoS One, vol. 12, no. 1, p. e0167488, 2017.
A. C. Galassie, Goll, J. B., Samir, P., Jensen, T. L., Hoek, K. L., Howard, L. M., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Hill, H., Joyce, S., Edwards, K. M., and Link, A. J., “Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination.”, Proteomics, vol. 17, no. 12, 2017.
T. L. Jensen, Frasketi, M., Conway, K., Villarroel, L., Hill, H., Krampis, K., and Goll, J. B., “RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting.”, F1000Res, vol. 6, p. 2162, 2017.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
M. J. Mulligan, Stapleton, J. T., Keitel, W. A., Frey, S. E., Chen, W. H., Rouphael, N., Edupuganti, S., Beck, A., Winokur, P. L., Sahly, H. M. El, Patel, S. M., Atmar, R. L., Graham, I., Anderson, E., El-Kamary, S. S., Pasetti, M. F., Sztein, M. B., Hill, H., and Goll, J. B., “Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.”, Vaccine, vol. 35, no. 36, pp. 4730-4737, 2017.
2016
I. N. Mbawuike, Atmar, R. L., Patel, S. M., Corry, D. B., Winokur, P. L., Brady, R. C., Chen, W. H., Edwards, K. M., C Creech, B., Walter, E. B., Frey, S. E., Belshe, R. B., Goll, J. B., Hill, H., and Keitel, W. A., “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
D. F. Hoft, Lottenbach, K., Goll, J. B., Hill, H., Winokur, P. L., Patel, S. M., Brady, R. C., Chen, W. H., Edwards, K., C Creech, B., Frey, S. E., Blevins, T. P., Salomon, R., and Belshe, R. B., “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.”, J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
2015
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.”, Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., “Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.”, J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
2014
F. M. Munoz, Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., and Nesin, M., “Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.”, Clin Infect Dis, vol. 59 Suppl 7, pp. S415-27, 2014.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., C Creech, B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., “Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.”, Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
R. L. Atmar, Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H., Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y., “Determination of the 50% human infectious dose for Norwalk virus.”, J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M. El, Spearman, P., Rouphael, N., Rudge, T. L., Hill, H., and Goll, J. B., “Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.”, Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.